Body weight considerations Unlike some peptides where dosing scales with body weight, cagrilintide uses fixed doses across weight categories in clinical trials
Tablets allow consistent delivery of the same amount during each test cycle
In REDEFINE 1 , a 68-week, Phase 3a, multicenter, double-blind, placebo- and active-controlled trial, 3,417 adults with overweight or obesity but without diabetes were randomized to CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg), semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo
Neuron, 89 (4), 695-710
Discover the rejuvenating benefits of PDO Threads during a personalized consultation
BPC-157 and TB-500 results are best evaluated with your provider so you can adjust the protocol if needed